company background image
A092

NeoPharm KOSDAQ:A092730 Stock Report

Last Price

₩23.00k

Market Cap

₩182.2b

7D

-2.5%

1Y

-36.0%

Updated

24 May, 2022

Data

Company Financials +
A092730 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance2/6
Financial Health6/6
Dividends4/6

A092730 Stock Overview

NeoPharm CO., LTD. manufactures and sells skin care products in South Korea.

NeoPharm Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for NeoPharm
Historical stock prices
Current Share Price₩23,000.00
52 Week High₩39,000.00
52 Week Low₩22,250.00
Beta1.02
1 Month Change-13.04%
3 Month Change-10.85%
1 Year Change-36.02%
3 Year Change-49.34%
5 Year Change-22.69%
Change since IPO176.85%

Recent News & Updates

Mar 28
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

A092730KR Personal ProductsKR Market
7D-2.5%1.0%1.2%
1Y-36.0%-44.6%-14.3%

Return vs Industry: A092730 exceeded the KR Personal Products industry which returned -44.6% over the past year.

Return vs Market: A092730 underperformed the KR Market which returned -14.3% over the past year.

Price Volatility

Is A092730's price volatile compared to industry and market?
A092730 volatility
A092730 Average Weekly Movement3.2%
Personal Products Industry Average Movement6.3%
Market Average Movement5.4%
10% most volatile stocks in KR Market10.2%
10% least volatile stocks in KR Market3.1%

Stable Share Price: A092730 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: A092730's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000135Byeong-Deog Parkhttps://www.neopharm.co.kr

NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELETCARE brand.

NeoPharm Fundamentals Summary

How do NeoPharm's earnings and revenue compare to its market cap?
A092730 fundamental statistics
Market Cap₩182.22b
Earnings (TTM)₩16.91b
Revenue (TTM)₩87.32b

10.6x

P/E Ratio

2.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A092730 income statement (TTM)
Revenue₩87.32b
Cost of Revenue₩25.69b
Gross Profit₩61.63b
Other Expenses₩44.73b
Earnings₩16.91b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.16k
Gross Margin70.58%
Net Profit Margin19.36%
Debt/Equity Ratio0.01%

How did A092730 perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

32%

Payout Ratio

Valuation

Is NeoPharm undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


31.7%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: A092730 (₩23000) is trading below our estimate of fair value (₩33685.8)

Significantly Below Fair Value: A092730 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: A092730 is good value based on its Price-To-Earnings Ratio (10.6x) compared to the KR Personal Products industry average (15.7x).

PE vs Market: A092730 is good value based on its Price-To-Earnings Ratio (10.6x) compared to the KR market (14.1x).


Price to Earnings Growth Ratio

PEG Ratio: A092730 is poor value based on its PEG Ratio (1.3x)


Price to Book Ratio

PB vs Industry: A092730 is good value based on its Price-To-Book Ratio (1.4x) compared to the KR Personal Products industry average (1.6x).


Future Growth

How is NeoPharm forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: A092730's forecast earnings growth (8.4% per year) is above the savings rate (3.5%).

Earnings vs Market: A092730's earnings (8.4% per year) are forecast to grow slower than the KR market (14.6% per year).

High Growth Earnings: A092730's earnings are forecast to grow, but not significantly.

Revenue vs Market: A092730's revenue (6.8% per year) is forecast to grow slower than the KR market (9.6% per year).

High Growth Revenue: A092730's revenue (6.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A092730's Return on Equity is forecast to be low in 3 years time (13.8%).


Past Performance

How has NeoPharm performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


12.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A092730 has high quality earnings.

Growing Profit Margin: A092730's current net profit margins (19.4%) are lower than last year (21.7%).


Past Earnings Growth Analysis

Earnings Trend: A092730's earnings have grown by 12.6% per year over the past 5 years.

Accelerating Growth: A092730's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A092730 had negative earnings growth (-8.5%) over the past year, making it difficult to compare to the Personal Products industry average (5%).


Return on Equity

High ROE: A092730's Return on Equity (13%) is considered low.


Financial Health

How is NeoPharm's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A092730's short term assets (₩127.3B) exceed its short term liabilities (₩19.0B).

Long Term Liabilities: A092730's short term assets (₩127.3B) exceed its long term liabilities (₩186.8M).


Debt to Equity History and Analysis

Debt Level: A092730 has more cash than its total debt.

Reducing Debt: A092730's debt to equity ratio has reduced from 0.3% to 0.01% over the past 5 years.

Debt Coverage: A092730's debt is well covered by operating cash flow (100003.6%).

Interest Coverage: A092730 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is NeoPharm current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


3.04%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: A092730's dividend (3.04%) is higher than the bottom 25% of dividend payers in the KR market (0.84%).

High Dividend: A092730's dividend (3.04%) is in the top 25% of dividend payers in the KR market (2.75%)


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, A092730 has been paying a dividend for less than 10 years.

Growing Dividend: A092730's dividend payments have increased, but the company has only paid a dividend for 3 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (32.4%), A092730's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (29.2%), A092730's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Byeong-Deog Park (55 yo)

no data

Tenure

Byeong-Deog Park serves as Chief Executive Officer and President of Neopharm Co Ltd. Byeong-Deog Park served at Basic Materials Research Department of Aekyung Industrial Co., Ltd. Byeong-Deog Park holds a...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

NeoPharm CO., LTD.'s employee growth, exchange listings and data sources


Key Information

  • Name: NeoPharm CO., LTD.
  • Ticker: A092730
  • Exchange: KOSDAQ
  • Founded: 2000
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: ₩182.221b
  • Shares outstanding: 7.82m
  • Website: https://www.neopharm.co.kr

Number of Employees


Location

  • NeoPharm CO., LTD.
  • 309-8, Techno 2-ro
  • Yuseong-gu
  • Daejeon
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.